NASDAQ
22.77USD
-29.75 (-56.65%)
We have scored 17 news catalysts on Veracyte, Inc. (VCYT) over the past 12 months. The biggest single-day move next to one of them came Nov 5, 2026, when VCYT closed −56.0%: “What Veracyte (VCYT) Said on Its Q3 Earnings Call”. Coverage across the window leans positive (average ticker sentiment +0.45). Most of the impact sits in forward growth expectations and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.8B
P/E
—
EPS
—
Beta
1.96
52W range
22-60.91
Day range
22.00–29.79
Open
29.27
Prev close
52.52
Volume
10.1M
Avg volume
1.3M
Dividend
0.00
IPO
2013-10-29
Analysts publish price targets on VCYT, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
11 analyst price targets from $44 to $69
as of 2026-09-24
The market is 23% below the median target — more cautious than the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Veracyte, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for VCYT: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
The price at $22.77 sits at the very bottom of the published model range ($44 to $69), rejecting eight bull cases and fully endorsing only the view that growth will decelerate to the high-single digits.
What the disagreement turns on
Does the launch of Prosigna and TrueMRD actually accelerate revenue growth back above the roughly 9% the price requires, and the wired data can only partially settle this by tracking overall unit volumes rather than product-specific adoption.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $43.82 on 2026-09-24 — the quote has since moved -48%, so read this as a record of what was priced in then, not now.
